pharmaphorum

JUNE 23, 2022

Novartis has shouldered its way into the in vivo gene editing category via a deal with US biotech Precision BioSciences, focused on a therapy for sickle cell disease (SCD). It is also working with Eli Lilly on in vivo gene-editing drugs against three targets, including one in Duchenne muscular dystrophy, under the terms of a $1.4

Gene Editing 97

Gene Editing In-Vivo Gene Sequencing Gene 97

Medical Xpress

FEBRUARY 1, 2023

Next-generation cancer strategies rely on next-generation gene sequencing (NGS), which paves the way for new techniques and tools to detect mutations and determine patient therapy.

Gene Sequencing 75

Gene Sequencing Gene Research Genetics 75

pharmaphorum

AUGUST 10, 2021

The three-year project – led by respiratory medicine expert Dr Timothy Hinks from the Oxford University Respiratory Medicine Unit – will use whole-genome sequencing of around 500 patients with severe asthma, comparing their gene sequences with control subjects who don’t have asthma. Dr Timothy Hinks.

Gene Sequencing 116

Gene Sequencing Gene Bioinformatics Genome 116

pharmaphorum

APRIL 23, 2021

Vertex Pharma has ramped up its involvement in gene-editing medicines for the second time in a week, paying Obsidian Therapeutics $75 million upfront to access its technology platform. . Alternatively, a drug can be administered that switches off the genetic medicine and brings protein expression to a halt.

Gene Editing 52

Gene Editing Genetics Drugs Gene 52

pharmaphorum

SEPTEMBER 14, 2022

SparingVision has raised €75 million in second-round funding that will be used to fund clinical trials of gene therapies for ocular diseases retinitis pigmentosa (RP) and dry age-related macular degeneration (AMD). The post SparingVision raises €75m for eye disease gene therapies appeared first on.

Gene Therapy 52

Gene Therapy Gene Gene Sequencing Gene Editing 52

Roots Analysis

OCTOBER 16, 2023

DNA and Gene Cloning involves the isolation of a DNA sequence of any species ( often a gene ) and its insertion into a vector to enable growth without any alteration in the original DNA sequence. There are some motifs, such as hairpin loops which hinder the usability of a gene.

DNA 40

DNA Gene Protein In-Vitro 40

Roots Analysis

FEBRUARY 23, 2022

Next Generation Sequencing (NGS) Library Preparation Kits. Driven by the increasing demand for gene therapies and the introduction of novel and advanced NGS techniques, the market is poised to grow at a CAGR of 18%, during the time period 2021-2035. Likely Growth of the NGS Library Preparation Kits Market. Our Social Media Platform.

Genetics 52

Genetics DNA RNA Reagent 52

The Pharma Data

DECEMBER 28, 2020

About Fulgent Genetics. Fulgent Genetics’ proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. TEMPLE CITY, Calif.,

Genetics 52

Genetics Sales Gene Sequencing Marketing 52

Roots Analysis

FEBRUARY 21, 2022

Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine.

Marketing 52

Marketing Gene Sequencing DNA Genome 52

pharmaphorum

FEBRUARY 22, 2021

Bluebird Bio’s decision to hit pause on the launch of Zynteglo for beta thalassaemia after two cases of cancer were seen in a clinical trial could see fears over the safety of viral vectors used to deliver gene therapies resurface. . million in Europe.

Gene Therapy 52

Gene Therapy Gene Gene Sequencing Gene Expression 52

pharmaphorum

AUGUST 21, 2020

Cambridge, UK-based Biofidelity has raised $12 million in first-round funding for its cancer diagnosis platform, which can detect mutations quicker than current approaches like gene sequencing. Longwall Ventures and Agilent have both returned to invest in the Series A, which on this occasion was led by BlueYard Capital.

DNA 59

DNA Gene Sequencing Genetics FDA Approval 59

FDA Law Blog

OCTOBER 24, 2024

Rather, developers of diagnostic tests and, indeed of any product that relies on free access to gene sequence and other biomarker information, should pay also close attention, as PERA would overturn longstanding judicial precedent. By 2010, about 2000 isolated human genes had been patented in the U.S.

Gene 64

Gene DNA Genetics Gene Sequencing 64

Pharmaceutical Technology

MAY 26, 2023

Tripling its production capacity, Touchlight can now manufacture 8kg plasmid DNA, a key component for mRNA gene therapies and vaccines. As per the company, dbDNA is suitable for rapid, scalable manufacture of GMP DNA and can incorporate gene sequences of sizes ranging from 500bp to 20kb, which are typically unstable as pDNA.

DNA 130

DNA Manufacturing Gene Gene Therapy 130